Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia

Jeffrey K. Yao¹,²,³*, Ruth Condray¹,², George G. Dougherty Jr.¹,², Matcheri S. Keshavan²,⁴, Debra M. Montrose⁵, Wayne R. Matson⁵, Joseph McEvoy⁶, Rima Kaddurah-Daouk⁶, Ravinder D. Reddy¹,²

¹ Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States of America, ²Department of Psychiatry, Western Psychiatric Institute & Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America, ³Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, United States of America, ⁴Beth Israel Deaconess Medical Center and Harvard University, Boston, Massachusetts, United States of America, ⁵Bedford Veterans Affairs Medical Center, Bedford, Massachusetts, United States of America, ⁶Duke University Medical Center, Durham, North Carolina, United States of America

Introduction

There is abundant evidence for impaired antioxidant defense system (AODS) and presence of oxidative stress in patients with schizophrenia (SZ) [1–6], suggesting that free radical-mediated pathology may have a role in the pathophysiology of SZ.

Free radicals are reactive chemical species generated during normal metabolic processes involving oxygen and nitric oxide, which in excess can lead to membrane damage. Under physiological conditions the potential for free radical-mediated damage is kept in check by the AODS, comprising a series of enzymatic and non-enzymatic components. These enzymes act cooperatively at different sites in the free radical pathways. We have previously observed that a dynamic state is kept in check during the redox coupling under normal conditions [7–8]. By contrast, lack of such correlations in brains of SZ patients point to a disturbance of redox coupling mechanisms in the AODS, possibly resulting from a decreased level of glutathione (GSH) as well as age-related decreases of oxidized GSH and glutathione reductase activities.

In addition to GSH redox coupling mechanism, purine catabolism may be an underappreciated component of the homeostatic response of mitochondria to oxidant stress and may play a critical role in slowing progressive mitochondrial dysfunction in certain disease states [9]. In response to oxidative stress, decreased energy charge or nucleic acid damage, purine metabolism shifts to favor breakdown to xanthine and uric acid.

Abstract

Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia.

Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naïve patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symptoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions.

Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.

* E-mail: jkyao@pitt.edu

Acknowledgments: This work was supported by VA Merit Review and the Stanley Plan (RKD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

Competing Interests: Dr. McEvoy received honoraria from Lilly, Merck, and Sunovion, and grant supports from Merck, Psychogenics, Roche, and Sunovion. Dr. Kaddurah-Daouk is a co-inventor on a series of patents in the metabolomics field. (1. One patent issued (3/20/12) “Lipidomic approaches to determine drug response – Phenotypes in cardiovascular disease” Patent # 8137977, expires 12/10/27. 2. One patent pending: “Lipidomic approaches for central nervous system disorders” Application # 12/091,213 filed 12/10/08, Publication # US 2009/0305323 12/10/10.) All other authors declare no conflict of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Citation: Yao JK, Condray R, Dougherty GG Jr, Keshavan MS, Montrose DM, et al. (2012) Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia. PLoS ONE 7(8): e42165. doi:10.1371/journal.pone.0042165

Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan

Received March 19, 2012; Accepted July 2, 2012; Published August 14, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This material is based on work supported in part by the grants from the Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research & Development (Merit Reviews (JKY) and Senior Research Career Scientist Award (JKY)), VA Pittsburgh Healthcare System (JKY, GGD), National Institutes of Health (MH58141 (JKY), MH64118 (RDR), MH55203 (MSK), MH84941 (RKD), R24 GM078233 (RKD), cUL1 RR024153 and NIH/NCRR/GCRC Grant M01 RR00056), Metabolomics Research Network (RKD), Stanley Medical Research Institute (RKD), and National Alliance for Research on Schizophrenia and Affective Disorders (RKD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

Competing Interests: Dr. McEvoy received honoraria from Lilly, Merck, and Sunovion, and grant supports from Merck, Psychogenics, Roche, and Sunovion. Dr. Kaddurah-Daouk is a co-inventor on a series of patents in the metabolomics field. (1. One patent issued (3/20/12) “Lipidomic approaches to determine drug response – Phenotypes in cardiovascular disease” Patent # 8137977, expires 12/10/27. 2. One patent pending: “Lipidomic approaches for central nervous system disorders” Application # 12/091,213 filed 12/10/08, Publication # US 2009/0305323 12/10/10.) All other authors declare no conflict of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: jkyao@pitt.edu
Recently, we [8] have further shown that a shift favorable to Xanthosine production from Xanthine, resulting in decreased uric acid (UA) levels in the first-episode neuroleptic-naive patients with schizophrenia (FENNS). Specifically, the reduced UA/guanosine ratio was nearly normalized after 4-week of antipsychotic treatment. In addition, there are tightly correlated precursor and product relationships within purine pathways; although some of these correlations persist across disease or medication status, others appear to be lost among FENNS. Taken together, these results suggest that the potential for steady formation of antioxidant UA from purine catabolism is altered early in the course of illness.

In this study, we extend our previous findings [8] to test whether homeostatic imbalance in purine catabolism is associated with specific clinical characteristics observed in FENNS at baseline and/or 4 weeks after antipsychotic treatment.

**Materials and Methods**

First-Episode Neuroleptic-Naive (FENN) Patients

Twenty five patients were recruited (Table 1) in their first episode of psychosis after they provisionally met DSM-IV criteria for schizophrenia, schizophreniform or schizoaffective disorder based on Structured Clinical Interview for DSM Disorders (SCID). The initial diagnostic assessments were performed at consensus diagnostic conferences including SCID and all clinical data, and attended by research faculty and staff, chaired by one of the authors (MSK or DM). All subjects signed informed consent after a full explanation of the study. The study was approved by both VA Pittsburgh Healthcare System and the University of Pittsburgh Institutional Review Board.

Blood samples were obtained in patients at baseline (FENNS-BL) prior to the initiation of antipsychotic agents. A second set of blood samples was obtained in the same patient individuals about 6 weeks after initiation of treatment (FENNS-6w) with one or more of the following antipsychotic drugs: risperidone (n = 17), olanzapine (n = 5), quetiapine (n = 2), aripiprazole (n = 1) and haloperidol (n = 2). The number adds up to more than 25 because of polypharmacy.

Clinical symptoms were rated by experienced research clinicians at both time points using standard rating scales. Our primary question concerned the association between purine catabolism and the severity of psychiatric disturbance in patients during the early phase of their illness. Severity of clinical presentation was evaluated using the Global Assessment Scale (GAS), which has a high degree of sensitivity to clinical change over time [10]. The relationships among purine metabolites and specific clinical symptom dimensions were additionally explored and included ratings of positive and negative symptoms (Positive Symptoms scale from the Brief Psychiatric Rating Scale (BPRS) [11]; Scale for Assessment of Negative Symptoms (SANS) [12]) and neurological symptoms (Neurological Evaluation Scale (NES) [13]). As expected, patients showed improvement in clinical symptoms and clinical functioning after 4 weeks of treatment with antipsychotic drugs (Table 2).

**Sample Preparation**

All blood samples were collected in the morning after overnight fasting. Samples were prepared for analysis by extraction in acidified acetonitrile and analyzed by liquid chromatography with electrode Coual Array (LCECA) system as previously described [8,14–15]. Briefly, freshly drawn blood with anticoagulant citrate dextrose (ACD) was centrifuged at 750 g for 7 minutes to remove RBC and stored at −80°C freezer. 250 μl aliquot of stored sample was mixed with 1 ml of acetonitrile/0.4% acetic acid at −25°C and vortexed for 45–60 sec, then temperature was brought to −15°C in a cold block, and vortexed again for 30–45 sec. Samples were centrifuged for 15 min at 12,000 x g at 4°C. In total, 1 ml of the resulting supernate was transferred to a 2 ml screw top vial and evaporated under vacuum. It is critical that the vacuum is sufficient to freeze the sample during this step. The sample was reconstituted in 200 μl of mobile phase A and 100 μl were loaded onto two autosampler vials, one of which was archived at −80°C. Profiles are stable in acetonitrile extract, dried extract and mobile phase diluted extract.

During the sample preparation, pools were created from equal volumes of aliquots of all samples. All assays were run in sequences that include 10 samples, authentic reference standard mixtures of 80 known compounds, pools of all samples and duplicate preparations of the same sample. Duplicates are spaced at short and long intervals through the run to reflect the performance of the total data base. Run orders of all samples in this study were randomized. The sequences minimized possible analytical artifacts during further data processing. Pools and duplicates were used to access the precision of the entire data set. In addition, the pools were used as references for time normalization (stretching). A practical advantage of LCECA for this study is the relative freedom from maintenance events. This is important for the generation of consistent databases from large numbers of samples over extended time periods. In our earlier work we have run LCECA continuously for 24 h per day over 6 months.

**High-Pressure Liquid Chromatography Coupled With Electrochemical Coulometric Array (LCECA) Detection**

The LCECA method used in this work has been described earlier [8,14–16]. Briefly the liquid chromatographic method employs an A mobile phase (10.3 g l−1 sodium pentane sulfonate, 5 ml l−1 glacial acetic acid) and a B mobile phase (methanol/acetonitrile/isopropanol 8/1/1, 8 g l−1 lithium acetate, 20 ml l−1 glacial acetic acid). A gradient is run from 100% A to 100% B over 120 min. The electrochemical array of 16 series coulometric detectors is set from 0 to 900 mv in equal 60 mv increments from detector 1–16. In this mode a compound passing through a coulometric electrode is oxidized by 100% of the thermodynamically possible amount. This results in a characteristic signature for a compound expressed as a ratio on sequential electrodes. This ratio provides a high degree of qualitative certainty, which can be set for any particular study [17]. The gradient and detector conditions typically provide responses at the 500 pg ml−1 level (5 pg on column) for ca 1500–2000 compounds in biological samples. In comparison with Mass Spectrometry (MS) a specific thermodynamically determined response ratio and retention time in an LCECA method does not carry as much qualitative certainty as an accurate mass peak or fragmentation pattern in MS/MS.

---

**Table 1. Subject characteristics of first-episode neuroleptic-naive patients with schizophrenia.**

| Demographical features | Male | Female |
|------------------------|------|--------|
| Number                 | 19   | 6      |
| Age (yrs, mean ± SD)   | 21.4±5.5 | 26.3±10.6 |
| Educations (yrs)       | 11.8±2.9 | 12.3±4.6 |
| Weight (lbs)           | 156.1±43.5 | 120.0±19.2 |
| Height (inches)        | 68.2±4.1 | 64.3±1.7 |
| Body mass index (BMI)  | 23.9±4.8 | 20.7±3.0 |

doi:10.1371/journal.pone.0042165.t001
However, in comparison with MS for the classes of compounds measurable on LCECA the sensitivity of ca 500 pg ml\(^{-1}\) is typically one to two orders of magnitude lower than can be achieved with MS. As an example we conducted a study directed at identifying metabolites implied by the presence of multiple responses in an LCECA method following Huntington’s disease patients treated with phenyl butyrate [18]. The LCECA method employed 40 \(\mu\)l of plasma. It was necessary to concentrate and fractionate 4 ml of plasma to obtain sufficient material for qualitative identification in a parallel LCECA/LCMS system. The LCECA method with 100% efficient electron transfer also has an inherent quantitative control based on integration of the total coulombs of the peaks [18] and calculation of quantity by Faraday’s law. Thus, it is independent of such factors as variations in ionization efficiency as a result, for instance, of column bleed.

Inter-laboratory/inter-method comparisons are a field in and of themselves. Well designed studies are highly expensive and have to take into account standards, preparative methods, sample splitting techniques and so on, as well as the instrumentation and parameters of instrument usage. Initial efforts are frequently discouraging. As an example the initial round of the multi-center/multi-method ESCOT study for 8 hydroxy 2’deoxyguanosine measurements initially returned values differing by a factor of 1000 with the higher values resulting from source artifacts in a gas chromatography-mass spectrometry (GC-MS) method.

Enzyme-linked immunosorbent assay techniques for this same analyte in urine are typically comparable to electrochemical methods for controls and standards but a factor of 2–5 higher in various disorders, whereas GC-MS techniques for this analyte in CSF have been reported as 10,000 times higher compared with electrochemical techniques.

### Statistical Analyses

The relationship between the purine analytes and clinical symptom ratings was examined for both time points. Descriptive statistics are provided in Yao et al. [8,15] for the purine metabolites and tests of differences for these analytes between baseline and 4 weeks for patients, as well as comparisons between the analyte levels of age-matched healthy volunteers and patients at each time point. The focus of the present report concerns the relationships between ratings of clinical symptoms for this sample of FENNS patients and plasma levels of those metabolites that previously showed altered interactions within the purine pathway [8]: (1) single metabolites, including guanine, guanosine, xanthosine, xanthine, uric acid; (2) ratios of product to precursor, including guanine/guanosine, xanthine/guanine, uric acid/guanosine, uric acid/guanine, uric acid/xanthosine, xanthosine/guanosine, xanthosine/guanine. Tests of the hypothesis that correlation coefficients involving the selected purine analytes and clinical symptoms were equal to zero were computed separately for the data recorded at baseline and the data measured at four weeks. Normality of data was estimated with Shapiro-Wilk Test of Normality (\(p>0.05\)); variables determined to approximate, or able to be transformed (ln, natural log) to approximate, normality were evaluated using parametric tests (paired-samples \(t\)-test; Pearson \(r\) correlation coefficient). Non-parametric tests (related-samples Wilcoxon Signed Rank Test; Kendall \(\tau\) rank correlation coefficient) were used for those measures determined not normally distributed. Bonferroni correction was applied to control Type I error potentially associated with the multiple tests of our primary question, which involved 12 measures of purine catabolism at the two time points and improvement in patients’ psychiatric disturbance (GAS, Global Assessment Scale) after one month of neuroleptic treatment: adjusted \(\alpha\) for 24 comparisons: 0.05/24 = 0.0021; trend significance: 0.10/24 = 0.0042. Tests of the hypothesis that correlations at baseline and at 4 weeks were equal were additionally computed to screen for any baseline-to-four week between group (unmedicated versus medicated) correlation differences. This test for the difference between dependent correlations was computed using the procedure described by Bruning and Kintz [19].

### Results

The ratio of uric acid/guanine measured at baseline predicted improvement in clinical adjustment (GAS score at 4 weeks minus GAS score at baseline) after four weeks of treatment with neuroleptic drug. Following normalization of the data by natural log, this association was statistically significant (Pearson \(r = -0.643\), \(p = 0.001\)), and involved an inverse relationship indicating that a lower initial proportion of product (uric acid) to precursor (guanine) was associated with greater improvement in clinical adjustment one month later (Figure 1A). In contrast, the association between the ratio of uric acid to guanine ratio measured at four weeks and clinical improvement (GAS scores) four weeks following initiation of neuroleptic treatment was not significant (Pearson \(r = -0.215\), \(p = 0.30\)) (Figure 1B). The difference between these two correlations was statistically significant (\(r = -2.32\), \(df = 22\), \(p<0.05\)).

Correlation coefficients for the relationships obtained between the selected purine analytes and clinical symptoms are presented in Table 3 for the data recorded at baseline and in Table 4 for the data collected at four weeks.

Findings from our exploration of associations among purine metabolites and specific symptom dimensions are additionally suggestive about domains of behavior that may be influenced by an imbalance in purine catabolism. Because of the exploratory nature of these latter analyses, \(p\)-levels were not corrected. Results

#### Table 2. Clinical assessments of first-episode neuroleptic-naïve patients with schizophrenia (n = 25).

| Rating scales | Baseline | 4-wk follow-up | \(p\) |
|---------------|----------|----------------|------|
| Brief Psychiatric Rating Scale (total)* | 52.58±8.90 | 42.92±7.50< | <0.001\(^7\) |
| Brief Psychiatric Rating Scale–Positive Symptoms | 15.72±3.25 | 11.80±4.29 | 0.001\(^1\) |
| Scale for Assessment of Negative Symptoms | 45.08±10.30 | 43.00±9.09 | 0.410\(^7\) |
| Global Assessment Scale | 30.40±9.10 | 37.76±11.79 | 0.001\(^1\) |

*missing data for 1 patient.
\(^1\)Paired samples \(t\)-test.
\(^7\)Related-samples Wilcoxon Signed Rank Test.
showed that the ratio of xanthosine to guanosine at baseline was positively correlated with the neurological symptom involving the sequencing of complex motor actions (Figure 2A). This ratio (xanthosine:guanosine) was also correlated with a factor that represents a composite of repetitive motor responses [20] (Figure 2B). Relationships were additionally observed between baseline guanosine levels and thought disturbance (Figure 3A), and between baseline uric acid levels and sensory integration (Figure 3B).

Discussion

Homeostatic imbalance of purine catabolism in schizophrenia

Increasing evidence suggests that mitochondrial pathology and oxidative stress may be one of the critical components in the pathophysiology and treatment outcome of schizophrenia [1–8]. Purine catabolism may contribute to mitochondrial antioxidant defense by producing the antioxidant uric acid [9]. Failure to maintain elevated xanthine and uric acid occurred contemporaneously with progressive mitochondrial dysfunction. On the other hand, increased levels of uric acid may be considered as a marker of oxidative stress [21,22] due to accumulation of reactive oxygen species [23]. Therefore, uric acid can be served as both anti- and prooxidant in the AODS.

In man, uric acid is the final product of purine catabolism [24], which has been implicated as a risk factor and cause of numerous pathological conditions. Abnormally high plasma (or serum) uric acid has been related to cardiovascular disease, gout, hypertension, and renal disease, whereas low levels of plasma (or serum) uric acid have been linked to Alzheimer’s disease, multiple sclerosis, optic neuritis, and Parkinson’s disease [6]. Previously, we have also demonstrated that plasma levels of uric acid are reduced in chronic [25] as well as first-episode neuroleptic-naive patients with schizophrenia [26]. Although some studies have indicated that uric acid may play a role in the development or progression of such diseases, it remains unclear whether an increased uric acid contributes to the cause or is simply a consequence of these pathologic conditions [27].

Moreover, in healthy control subjects, there exist tight product-precursor correlations within purine catabolism [8]. Interestingly, some of these correlations (i.e., conversion of hypoxanthine to xanthine) persist across disease or medication status, others (i.e., conversions of guanosine to xanthine, and xanthine to uric acid) are lost among these same FENNS patients [8]. Similar findings of lacking a control mechanism used by healthy control subjects were also demonstrated in the tryptophan pathway from these same patient group [15], indicating some metabolite interactions within purine catabolism were altered in FENNS patients. Taken collectively, purine catabolism appears to be a homeostatic response of mitochondria to oxidative stress and may play protect against progressive mitochondrial dysfunction in schizophrenia. Thus, our data as well as findings from other investigators are consistent with the notion of free radical-mediated neurotoxicity in schizophrenia [1–6].

Purine metabolites and neurological symptoms

Neurological abnormalities are observed in schizophrenia patients even at the time of their first episode of psychosis and

![Figure 1. Associations between clinical improvement at 4 weeks and ratio of uric acid to guanine in first-episode neuroleptic-naive patients with schizophrenia at baseline (A) or at 4-week (B) after antipsychotic treatment. Abbreviations: GAS, Global Assessment Scale; In, natural logarithm. doi:10.1371/journal.pone.0042165.g001](https://www.plosone.org/doi/10.1371/journal.pone.0042165.g001)
of neuroanatomical regions that are relevant for some of the neuropsychological and cognitive performance in schizophrenia risk. Finally and importantly, neurological signs are predictive of abnormalities may represent a biological marker of schizophrenia findings has led some researchers to suggest that neurological neurologic-related responding [33]. This overall pattern of familial influence, has also been reported for several aspects of before the initiation of antipsychotic drug treatment [20,28–31]. Moreover, neurological signs are correlated with clinical symptoms in unmedicated patients [32]. Significant heritability, or familial influence, has also been reported for several aspects of neurologic-related responding [33]. This overall pattern of findings has led some researchers to suggest that neurological abnormalities may represent a biological marker of schizophrenia risk. Finally and importantly, neurological signs are predictive of neuropsychological and cognitive performance in schizophrenia patients and healthy individuals [20,34], and related to measures of neuroanatomical regions that are relevant for some of the cognitive deficits associated with this mental disorder [29,31]. Findings from our present study suggest such interrelationships are also associated with alterations in purine catabolism in schizophrenia.

Purine metabolites were also linked to neurological and cognitive symptoms in our exploratory analyses based on this sample of FENNS patients. Firstly, motor responses recorded at baseline were associated with initial or baseline level of the ratio of xanthosine to guanosine. As shown in Figure 2A and 2B, the direction of these relationships indicates that a higher initial proportion of product (xanthosine) to precursor (guanosine) was

**Table 3.** Correlation coefficients between purine metabolites and clinical assessments from first-episode neuroleptic-naive patients with schizophrenia at baseline before antipsychotic treatment.

| Purine metabolites | GAS  | BPRS-PSS | SANS  | BPRS-TD | SI   | MC   | RM   | SCMA |
|--------------------|------|----------|-------|---------|------|------|------|------|
| G*                 | 0.414| −0.099   | 0.062 | −0.132 | −0.324| 0.008| −0.205| −0.145|
| Gr*                | 0.151| −0.300   | −0.014| −0.323 | −0.298| 0.035| −0.234| −0.203|
| Xant*              | 0.153| 0.063    | −0.118| 0.069  | −0.311| −0.025| 0.092 | 0.203 |
| Xan*               | −0.014| 0.080    | 0.027 | −0.038 | −0.187| −0.025| −0.048| −0.123|
| UA*                | 0.033| −0.191   | −0.121| −0.207 | −0.402| −0.107| −0.317| −0.238|
| G/Gr*              | 0.224| 0.136    | 0.108 | 0.127  | 0.102 | −0.008| 0.110 | 0.114 |
| Xan/G*             | −0.486| 0.081    | −0.175| 0.119  | 0.145 | −0.008| 0.078 | −0.045|
| UA/Gr*             | −0.224| 0.260    | 0.033 | 0.294  | 0.261 | −0.107| 0.278 | 0.274 |
| UA/G*              | −0.643| −0.011   | −0.217| 0.039  | 0.050 | −0.090| 0.008 | 0.017 |
| UA/Xant*           | −0.170| −0.157   | 0.081 | −0.181 | 0.102 | −0.025| −0.206| −0.309|
| Xant/Gr*           | 0.172| 0.055    | −0.151| 0.110  | 0.054 | 0.008 | 0.491 | 0.506|
| Xant/G*            | −0.075| 0.045    | −0.141| 0.099  | −0.017| 0.057 | 0.206 | 0.258|

*Pearson correlation coefficient was calculated following transformation of the data (except MC) to natural logarithm. *Kendall’s tau rank correlation coefficient was measured when those data determined not normally distributed. Significance with p = 0.001 in boldface after the Bonferroni correction.

**Abbreviations:** G, guanine; Gr, guanosine; Xant, xanthosine; Xan, xanthine; UA, uric acid; GAS, Global Assessment Scale; BPRS, Brief Psychiatric Rating Scale; PSS, Positive Symptoms Scale; SANS, Scale for Assessment of Negative Symptoms; TD, Thought disorder; SI, Sensory Integration; MC, Motor Coordination; RM, Repetitive Motion; SCMA, Sequencing Complex Motor Acts.

doi:10.1371/journal.pone.0042165.t003

**Table 4.** Correlation coefficients between purine metabolites and clinical assessments from first-episode neuroleptic-naive patients with schizophrenia 4 weeks after initiating antipsychotic treatment.

| Purine metabolites | GAS  | BPRS-PSS | SANS  | BPRS-TD | SI   | MC   | RM   | SCMA |
|--------------------|------|----------|-------|---------|------|------|------|------|
| G*                 | 0.088| 0.021    | −0.215| 0.090  | −0.260| −0.108| −0.146| −0.072|
| Gr*                | −0.067| −0.004   | −0.178| 0.086  | −0.163| 0.012 | −0.088| −0.141|
| Xant*              | 0.456| −0.186   | −0.222| 0.011  | −0.146| 0.029 | −0.064| −0.094|
| Xan*               | −0.085| −0.111   | −0.051| −0.166 | −0.393| −0.264| −0.198| −0.127|
| UA*                | 0.061| −0.028   | −0.065| −0.015 | −0.343| −0.108| −0.070| 0.006 |
| G/Gr*              | 0.108| 0.021    | −0.099| 0.008  | −0.104| −0.147| −0.059| 0.028 |
| Xan/G*             | −0.297| −0.071   | 0.330 | −0.173 | 0.142 | −0.029| 0.057 | 0.072 |
| UA/Gr*             | 0.163| 0.081    | 0.108 | −0.068 | −0.096| −0.029| 0.090 | 0.072 |
| UA/G*              | −0.215| 0.038    | 0.303 | −0.008 | 0.128 | 0.069 | 0.165 | 0.112 |
| UA/Xant*           | −0.312| 0.143    | 0.070 | 0.015  | −0.117| 0.147 | −0.002| 0.028 |
| Xant/Gr*           | 0.436| −0.098   | 0.029 | −0.019 | 0.066 | 0.029 | 0.069 | 0.072 |
| Xant/G*            | 0.175| −0.126   | 0.082 | −0.098 | 0.192 | −0.010| 0.100 | 0.072 |

*Kendall’s tau rank correlation coefficient was measured when those data determined not normally distributed.

**Pearson correlation coefficient was calculated following transformation of the data (except those data from BPRS-TD, MC, and SCMA) to natural logarithm.

**Abbreviations:** See footnote of Table 3.

doi:10.1371/journal.pone.0042165.t004
Associated with greater impairment in motor tasks. Thus, the higher a patient's initial or baseline ratio of xanthosine to guanosine, the greater his or her motor impairment was before initiating treatment with antipsychotic medications. Secondly, sensory processing was predicted by baseline level of uric acid. The direction of this relationship, seen in Figure 3, suggests that lower levels of uric acid were associated with greater impairment in sensory processing tasks.

A commonality among these neurological symptoms is the degree of complexity of response that is required by the assessment tasks. In one of the tests that tap the ability to sequence complex motor acts, for example, the individual is asked to use a steady rhythmic pattern to touch the table first with his/her fist, then with the edge of his/her hand, and then with the palm of his/her hand. The individual is told to repeat this sequence 15 times [13]. The sensory tasks also demand complex processing and responding by requiring the integration of auditory, visual, and tactile stimulation followed by an action that involves either a verbal or other motor response, such as the placement of a hand or pointing of finger.

Our group has previously documented highly statistically significant associations between these neurologically-based behaviors and standard neuropsychological tests of memory and intelligence in patients with first-episode psychosis who were neuroleptic-naive at the time of testing [20]. The present report, which also involved FENNS patients, provides evidence of linkages between those same neurologically-based behaviors and metabolites within the purine pathway, which is closely linked to a series of enzymatic and non-enzymatic components collectively referred to as the AODS.

Associations among uric acid, which represents an endpoint of purine metabolism in humans, and intelligence and achievement were first reported in the modern research literature over five decades ago [35–37]. Of interest is the mention by Barrera et al. [38] of a connection made between uric acid and intelligence that appeared in the published literature as early as the 1600s. Present day discussions include the hypothesis that the relative increase in levels of uric acid in humans, compared to other mammals, may have conferred an evolutionary advantage [39]. Although attention to this topic declined during the mid-1980s and throughout much of the 1990s, recent reports are suggestive of a growing interest in the contribution of alterations in purine...
metabolism to illness and disability. Related evidence includes associations reported between low levels of uric acid and risk for Parkinson’s Disease (PD) [40], and between low levels of uric acid and reduced performance on neuropsychological tests of intelligence and attention in patients with this disease [41]. By contrast, associations have been reported between elevated levels of uric acid and motor behaviors, including increased uric acid and hyperactive behaviors in normal preschool children [39], increased uric acid and increased locomotor activity in rats [42], and an abnormal increase in level of uric acid and psychomotor excitation in schizophrenia patients during acute illness [43]. Beyond mammals, other evidence implicates a role for purines, including hypoxanthine and uric acid, in the sensitivity to external stimuli and motor responses of insects [44]. In combination with these findings from the research literature, our data are suggestive of some optimal level of purine byproducts and dynamics in the integrity of intelligence and manifest behavior.

Limitations

The present study is mainly involved in the purine metabolites of peripheral blood samples. Whether such an association between optimal levels of purine byproducts and dynamics in clinical symptoms is present in the brain awaits further investigation.

Acknowledgments

The authors are also grateful to Drs. Raymond Cho, Gretchen Haas, and Konasale Prasad, and the clinical core staff of the Center for the Neuroscience of Mental Disorders (David Lewis, M.D., Director) for their assistance in diagnostic and psychopathological assessments, and to P. Cheng, C. Korbanic and J. Haflett for their technical assistance. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

Author Contributions

Conceived and designed the experiments: JKY RDR MSK DAM. Performed the experiments: JKY WRM RK. Analyzed the data: JKY RC GGD. Contributed reagents/materials/analysis tools: JKY RR JM. Wrote the paper: JKY RC GGD.

References

1. Cadet JL, Lohr JB (1987) Free radicals and the developmental pathology of schizophrenia burnout. Integrative Psychiatry 5: 40–48.
2. Do KQ, Cabunagcal JH, Frank A, Steullet P, Cueneed M (2009) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19: 220–230.
3. Lohr JB (1991) Oxygen radicals and neuropsychiatric illness: Some speculations. Arch Gen Psychiatry 48: 1097–1106.
4. Matsuzawa D, Hashimoto K, Hashimoto T, Shimizu E, Watanabe H, et al. (2009) Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 150B: 86–94.
5. Reddy R, Yao J K (1996) Free radical pathology in schizophrenia: A review. Prostaglandins Leukot Essent Fatty Acids 55: 33–43.
6. Yao J K, Keshavan MS (2011) Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View. Antioxidants & Redox Signaling 15: 2011–2033.
7. Yao J K, Leonard S, Reddy R D (2006) Altered glutathione redox state in schizophrenia. Disease Markers 22: 83–93.
8. Yao J K, Dougherty GG, Reddy R D, Keshavan MS, Mourtos DM, et al. (2010) Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 5: e9508. doi:10.1371/journal.pone.0009508
9. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, Matson WR (1999) Purine Catabolism: Links to Mitochondrial Respiration and Antioxidant Defences. Arch Biochem Biophys 370: 22–33.
10. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766–771.
11. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10: 779–812.
12. Andreasen NC (1983) Scale for the Assessment of Negative Symptoms. Iowa City: University of Iowa Press.
13. Buchanan RW, Heinrichs DW (1989) The Neurological Evaluation Scale (NES): a unique approach to metabolomics. Methods Mol Biol 80: 5912–5923.
14. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, et al. (2009) Metabolic profiling to develop blood biomarkers for Parkinson’s disease. Brain 131: 389–396.
15. Yao J K, Dougherty GG, Reddy R D, Keshavan MS, Mourtos DM, et al. (2010) Altered interactions of tripyrines metabolites in first-episode neuropsychiatry-naïve patients with schizophrenia. Mol Psychiatry 15: 938–953.
16. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR (2007) High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 335: 159–176.
17. Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS (2002) Attention to relative response across sequential electrodes improves quantitation of coulometric array. Anal Biochem 302: 239–245.
18. Schiao S, Ebbel E, Sharma S, Matson W, Kristal BS, et al. (2008) Metabolite identification using a nanoelectrospray LC-EC-array integrated system. Anal Chem 80: 5912–5923.
19. Brunling KJ, Kintz BL (1987) Computational handbook of statistics (3rd ed.). Illinois: Scott, Foresman and Company.
20. Sanders RD, Schuepbach D, Goldenst G, Haas GL, Sweeney JA, et al. (2004) Relationships between cognitive and neurological performance in neuroleptic-naïve psychosis. J Neuropsychiatr Clin Neurosci 16: 480–487.
21. Becker BF (1995) Towards the physiological function of uric acid. J Free Radic Biol Med 14: 615–631.
22. Marazziti P, Paig JG (2007) Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 17: 409–414.
23. Hyden MR, Tyagi SC (2004) Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the newer redox shuttle. Nutr Metab (Lond) 1: 1–10.
24. Linden J, Krusin DL (2006) Purine system. In: Siegel JG, Albers RW, Brady ST, Price DL, editors. Basic Neurochemistry, Molecular, Cellular and Medical Aspects, 7th edition. Boston: Elsevier. pp. 303–316.
25. Yao J K, Reddy R, van Klaassen DP (1986) Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 89: 29–39.
26. Reddy RD, Keshavan MS, Yao J K (2003) Reduced plasma antioxidants in first-admission patients with schizophrenia. Schizophr Res 62: 205–212.
27. Koting MK, Firestein BL (2007) Altered uric acid levels and disease states. J Pharm Exp Therapeutics 324: 1–7.
28. Gupta S, Andreasen NG, Arrighi S, Flaum M, Schultz SK, et al. (1995) Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry 152: 191–196.
29. Keshavan MS, Sanders RD, Sweeney JA, Diwakar VA, Goldenst G, et al. (2003) Diagnostic specificity and neuropsychological validity of neurological abnormalities in first-episode psychoses. Am J Psychiatry 160: 1298–1304.
30. Mott FR, Hubein W, Aller R, Franz E, Hechtl S, et al. (2003) Neurological soft signs and psychological performance in patients with first episode schizophrenia. Psychiatry Res 121: 21–30.
31. Rubin P, Vorstrup S, Hemmingsen R, Andersen HS, Bendesen BB, et al. (1994) Neurological abnormalities in patients with schizophrenia or schizophreniform disorder at first admission to hospital: correlations with computerized tomography and regional cerebral blood flow findings. Acta Psychiatr Scand 90: 385–390.
32. Sanders RD, Keshavan MS, Forman SD, Peri JN, McLaughlin N, et al. (2000) Factor structure of neurological examination abnormalities in unmedicated schizophrenia. Psychiatry Res 95: 237–243.
33. Sanders RD, Joo YH, Almasy L, Wood J, Keshavan MS, et al. (2006) Are neurologic examination abnormalities heritable? A preliminary study. Schizophr Res 86: 172–180.
34. Arango C, Barrio JH, Gold JM, Buchanan RW (1999) Prediction of neuropsychological performance by neurological signs in schizophrenia. Am J Psychiatry 156: 1349–1357.
35. Stetten D J, Hearnan JZ (1959) Intellectual level measured by army classification battery and serum uric acid concentration. Science 129: 1737.
36. Kadi SV, Brooks GW, Rodgers WL (1976) Serum uric acid and cholesterol in achievement behavior and motivation: I. The relationship to ability, grades, test performance, and motivation. JAMA 213: 1158–1164.
37. Kadi SV, Brooks GW, Rodgers WL (1976) Serum uric acid and cholesterol in achievement behavior and motivation: II. The relationship to college attendance, extracurricular and social activities, and vocational aspirations. JAMA 213: 1291–1299.
38. Barrera CM, Ruiz ZR, Dunlap WP (1988) Uric Acid: A participating factor in the symptoms of hyperactivity. Biol Psychiatry 24: 344–347.
39. Álvarez B, Macarrón-Vicente J (2010) Uric acid and evolution. Rheumatology 49: 2010–2015.
40. de Lau LM, Koudstaal PJ, Hoffman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Annals Neurology 58: 797–800.
41. Annanmaki T, Pessala- Driver A, Høkkanen L, Murros K (2008) Uric acid associates with cognition in Parkinson’s disease. Parkinsonism and Related Disorders 14: 576–578.
42. Barrera CM, Hunter RE, Dunlap WP (1989) Hyperuricemia and locomotor activity in developing rats. Pharmacol Biochem Behavior 33: 367–369.
43. Nagamine T (2010) Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study. Neuropsychiatric Disease and Treatment 6: 291–298.
44. Ishay JS, Paniry VA (1979) Effects of caffeine and xanthines on hornets and bees. Psychopharmacology 65: 299–309.